|Bid||10.41 x 1200|
|Ask||10.53 x 1300|
|Day's Range||7.80 - 12.70|
|52 Week Range||0.71 - 12.77|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.40|
Stocks pared back losses Friday after President Donald Trump delivered a China-focused speech that was more restrained than expected. There was no talk of sanctions or raised tariffs on Chinese goods.
Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.
(Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical Oncology’s virtual annual meeting.Wall Street was quick to crown small-caps Adaptimmune Therapeutics Plc and Trillium Therapeutics Inc. as well as heavyweight AstraZeneca Plc among the early winners with shares rallying on the back of their respective updates. On the flip side, uninspiring results from Arvinas Inc.’s prostate cancer study and Aveo Pharmaceuticals Inc.’s kidney cancer trial drove investors to punish shares.Here’s a breakdown of some of ASCO’s biggest winners and losers:Adaptimmune TherapeuticsThe small developer of cell therapies more than doubled in Friday’s session after announcing updated early-stage results from a handful of trials in a range of cancer types. The company said its treatments drove responses in esophagogastric junction, lung, and head and neck cancer patients. Adaptimmune plans to start a mid-stage study of its therapy in esophagogastric junction cancer patients in the first half of next year.Trillium TherapeuticsThe hedge fund darling jumped as much as 21% after updated results for its early-stage study of TTI-622 showed a second patient responded to treatment with their cancer shrinking, providing further evidence that the drug could help patients with lymphoma that has progressed after trying previous therapies.Ladenburg Thalmann analyst Wangzhi Li wrote that the update showcased “excellent safety and surprising monotherapy activity” in the second patient. The 81-year-old patient’s response was classified as a partial response, but looked like it was almost a complete recovery with nearly 100% of the tumor reduced after eight weeks of follow-up.AstraZenecaShares of the pharmaceutical giant rallied as much as 3.4% in London after updates from a trio of key cancer drugs. The U.K. drugmaker said its blockbuster drug Tagrisso cut the risk of lung cancer death while studies of Imfinzi and Enhertu showed meaningful benefits for patients with small-cell lung cancer and gastric cancer.Autolus TherapeuticsAutolus was among the Nasdaq Biotechnology Index’s top performers Friday after announcing new data on its CAR-T cell therapy in patients with diffuse large B cell lymphoma. The updated results showed the medicine was well tolerated with no patients experiencing dose-limiting toxicity, and there were no treatment-related deaths.Aveo PharmaceuticalsAveo tumbled as much as 23%, the worst drop since early November, after late-stage results for its kidney cancer study showed its medicine didn’t extend lives longer than Bayer’s Nexavar. Aveo erased some of its loss after Baird raised its price target to a Street-high $24 from $15, saying the analysis removed an overhang on shares.ArvinasThe New Haven, Connecticut-based biopharma company sank 18% to make it the Nasdaq Biotech Index’s worst performer after updated results from its early-stage trial of ARV-110 in prostate cancer failed to excite investors. Just two of the 20 patients in the trial saw their PSA levels decline by 50% or more, missing many analyst expectations.MacroGenicsMacroGenics fell as much as 16% after releasing additional data for a trio of cancer drugs. Wall Street has been closely watching early data on MGD013 and MGC018 after bullish commentary from its management team earlier this month caused shares to triple.Allogene TherapeuticsShares of Allogene were little changed, erasing an initial drop, after updated results for its off-the-shelf CAR-T therapy showed a decline in patient benefit compared to an initial peek earlier this month. Twelve of 19 patients with blood cancer have responded to Allogene’s ALLO-501 in the “Alpha” study, including seven that had a complete response, the company said.Analysts had already started to debate whether the early-stage drug data that spurred Allogene to recored highs and a more than $6 billion valuation was warranted.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data.
Focused on using engineering cells to help the immune system recognize and fight cancer, the company made waves when it showed activity against solid tumors. The engineered T cells increase the immune system's ability to detect cancer cells and destroy them. This method of tweaking patients' own cells and then giving the cells back to them has led to two Food and Drug Administration (FDA) approved cell therapies: Yescarta from Gilead and Kymriah from Novartis.
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q1 2020 Earnings CallMay 14, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to the Adaptimmune Q1 2020 Earnings Conference Call.
Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.Outlook Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 14, 2020View more earnings on ADAPTime: 08:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/4772jrtcTechnicals 52-week high: $6.0052-week low: $0.71Price action over last quarter: Up 27.07%Company Description Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.See more from Benzinga * Meredith: Q3 Earnings Insights * Wabash National: Q1 Earnings Insights * Recap: Aemetis Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug.
- Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for.
If you own shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) then it's worth thinking about how it contributes to...
- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP),.
Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas. Adaptimmune’s SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) is actively enrolling at approximately 25 clinical sites in Canada, France, Spain, the United Kingdom, and the US. The SPEARHEAD-1 trial is intended to support the registration of ADP‑A2M4 for the treatment of advanced synovial sarcoma and MRCLS.
The final numbers are in: Passage Bio has raised a total of $248.4 million through its initial public offering, setting a new record for an IPO by a Philadelphia-area cell or gene therapy company. Passage Bio initially sold 12 million shares of its stock at $18 per share on Feb. 28, bringing in $216 million in the early days of what has been a volatile three-week run on Wall Street. The gene therapy company spun out of the University of Pennsylvania announced this week the underwriters for the offering exercised their full option to purchase an additional 1.8 million shares, raising the total value of the IPO to $248.4 million.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) just released its latest yearly report and things are not looking great. It...
- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -.
NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Adaptimmune Therapeutics Plc (NASDAQ:ADAP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27, ...
The company's new CEO has a new leadership team in place and money in the bank as its works to advance its cell therapies for solid tumors.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 20, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces.
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising additional net proceeds of approximately $11.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. After giving effect to the option exercise, Adaptimmune sold a total of 24,150,000 ADSs in connection with the offering, generating net proceeds of approximately $89.8 million, after deducting the underwriting discount and other offering expenses payable by Adaptimmune.